Poly Medicure Limited — Important, 03-02-2025: General Updates

**Financial Highlights:** Poly Medicure reported a consolidated revenue of ₹424.2 Cr for Q3, a 24.9% increase YoY, and ₹1229.0 Cr for 9M FY 25, rising 23.2% YoY. Consolidated PAT grew by 31.1% to ₹85.2 Cr in Q3 and 29.9% to ₹246.7 Cr in 9M FY 25. Key financial metrics also saw improvements, with EBITDA margins at 27.4% for both periods.

**Strategic Initiatives and Growth Drivers:** The company is focusing on R&D for breakthrough medical devices, enhancing manufacturing capacity to support global demand, and pursuing sustainable practices. A notable joint venture for a solar power plant and the establishment of a new manufacturing facility position Poly Medicure as a forward-thinking entity in the healthcare sector.

**Business Developments:** During the quarter, Poly Medicure received regulatory approval for a Drug Eluting Stent and signed a JV with AMPIN for a 9.9MW solar power plant. Revenue growth in domestic operations was 23.8% in Q3, while exports increased by 30.1%.

**Market Position and Competitive Advantage:** As a leader in the Indian medical device industry, Poly Medicure's robust infrastructure, strategic global partnerships, and commitment to innovation underscore its competitive edge, addressing a growing market for medical devices.

**Investor Implications:** Poly Medicure strategically positions itself for sustainable growth, with a focus on innovation and expanding into high-demand market segments. The company's solid financial performance and proactive initiatives suggest a positive outlook for investors. Keep a close watch on upcoming product introductions and market expansions.